vs
Side-by-side financial comparison of Essent Group Ltd. (ESNT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Essent Group Ltd. is the larger business by last-quarter revenue ($312.4M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). Essent Group Ltd. runs the higher net margin — 49.6% vs 1.6%, a 48.0% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -0.8%). Over the past eight quarters, Essent Group Ltd.'s revenue compounded faster (2.3% CAGR vs -0.2%).
Essentra PLC is a supplier of plastic and fibre products. The company operates internationally from headquarters in Kidlington, Oxfordshire. It is listed on the London Stock Exchange.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ESNT vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $312.4M | $177.4M |
| Net Profit | $155.0M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 59.1% | 3.9% |
| Net Margin | 49.6% | 1.6% |
| Revenue YoY | -0.8% | 5.0% |
| Net Profit YoY | -7.7% | — |
| EPS (diluted) | $1.61 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $312.4M | $196.9M | ||
| Q3 25 | $311.8M | $179.5M | ||
| Q2 25 | $319.1M | $181.1M | ||
| Q1 25 | $317.6M | $168.9M | ||
| Q4 24 | $315.0M | $187.3M | ||
| Q3 24 | $316.6M | $168.6M | ||
| Q2 24 | $312.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $155.0M | — | ||
| Q3 25 | $164.2M | $5.4M | ||
| Q2 25 | $195.3M | $-4.8M | ||
| Q1 25 | $175.4M | $4.8M | ||
| Q4 24 | $167.9M | — | ||
| Q3 24 | $176.2M | $-143.5M | ||
| Q2 24 | $203.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 59.1% | 1.2% | ||
| Q3 25 | 63.9% | 3.5% | ||
| Q2 25 | 72.4% | 4.7% | ||
| Q1 25 | 65.2% | 1.2% | ||
| Q4 24 | 61.9% | 13.2% | ||
| Q3 24 | 65.6% | -82.8% | ||
| Q2 24 | 76.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 49.6% | — | ||
| Q3 25 | 52.7% | 3.0% | ||
| Q2 25 | 61.2% | -2.7% | ||
| Q1 25 | 55.2% | 2.8% | ||
| Q4 24 | 53.3% | — | ||
| Q3 24 | 55.6% | -85.1% | ||
| Q2 24 | 65.1% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $1.61 | $0.05 | ||
| Q3 25 | $1.67 | $0.12 | ||
| Q2 25 | $1.93 | $-0.11 | ||
| Q1 25 | $1.69 | $0.10 | ||
| Q4 24 | $1.59 | $0.38 | ||
| Q3 24 | $1.65 | $-3.11 | ||
| Q2 24 | $1.91 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.8B | $653.9M |
| Total Assets | $7.4B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $5.8B | $693.1M | ||
| Q3 25 | $5.7B | $727.2M | ||
| Q2 25 | $5.7B | $757.8M | ||
| Q1 25 | $5.7B | $798.5M | ||
| Q4 24 | $5.6B | $778.3M | ||
| Q3 24 | $5.6B | $749.6M | ||
| Q2 24 | $5.4B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $7.4B | $1.3B | ||
| Q3 25 | $7.4B | $1.3B | ||
| Q2 25 | $7.2B | $1.5B | ||
| Q1 25 | $7.2B | $1.6B | ||
| Q4 24 | $7.1B | $1.6B | ||
| Q3 24 | $7.1B | $1.5B | ||
| Q2 24 | $6.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $856.1M | — |
| Free Cash FlowOCF − Capex | $848.7M | — |
| FCF MarginFCF / Revenue | 271.7% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | 5.52× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.5B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $856.1M | $43.7M | ||
| Q3 25 | $215.9M | $60.8M | ||
| Q2 25 | $189.5M | $12.0M | ||
| Q1 25 | $221.6M | $35.5M | ||
| Q4 24 | $861.5M | $33.1M | ||
| Q3 24 | $229.2M | $53.9M | ||
| Q2 24 | $188.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $848.7M | $43.5M | ||
| Q3 25 | $210.6M | $57.0M | ||
| Q2 25 | $188.8M | $9.3M | ||
| Q1 25 | $221.3M | $26.9M | ||
| Q4 24 | $854.8M | $31.0M | ||
| Q3 24 | $228.7M | $49.8M | ||
| Q2 24 | $187.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 271.7% | 22.1% | ||
| Q3 25 | 67.5% | 31.7% | ||
| Q2 25 | 59.2% | 5.1% | ||
| Q1 25 | 69.7% | 15.9% | ||
| Q4 24 | 271.3% | 16.6% | ||
| Q3 24 | 72.2% | 29.6% | ||
| Q2 24 | 60.0% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 0.1% | ||
| Q3 25 | 1.7% | 2.2% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.1% | 5.1% | ||
| Q4 24 | 2.1% | 1.1% | ||
| Q3 24 | 0.2% | 2.4% | ||
| Q2 24 | 0.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 5.52× | — | ||
| Q3 25 | 1.31× | 11.20× | ||
| Q2 25 | 0.97× | — | ||
| Q1 25 | 1.26× | 7.37× | ||
| Q4 24 | 5.13× | — | ||
| Q3 24 | 1.30× | — | ||
| Q2 24 | 0.93× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESNT
| Mortgage Insurance Segment | $192.4M | 62% |
| Other | $120.0M | 38% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
